Breast cancer drug linked to brain malfunction

Toronto: A breast cancer drug reveals side-effects, including mood disturbances and memory issues, that impact the brain function in both humans and animals, say researchers.

The drug letrozole is used to prevent breast cancer recurrence by interfering with the production of estrogens.

For the study, researchers from the University of Toronto in Canada showed that they administered letrozole to male and female marmosets — a nonhuman primate model — for four weeks and observed many behavioural changes including hot flashes and increased anxiety, experienced by women receiving similar treatment.

In addition, letrozole also compromised the function of neurons in the hippocampus (organ located in the brain) and impaired spatial memory, results revealed, published in the Journal of Neuroscience.

Findings emphasise the need for further investigation of breast cancer treatments and their effects on the brain, the team noted.

Breast cancer is the top cancer in women worldwide and is increasing particularly in developing countries where a majority of cases are diagnosed in late stages.

  • Related Posts

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    New Delhi:  Aurobindo Pharma Ltd on Tuesday said it has set April 23 as the opening date for its Rs 800 crore buyback offer. The closing date for the buyback…

    Boehringer Ingelheim launches AI centre for pharma research in London

    Bengaluru: German drugmaker Boehringer Ingelheim is launching a ​centre for artificial ​intelligence and machine learning in London, it said ​on Monday, as it seeks to expand its AI capabilities in…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Boehringer Ingelheim launches AI centre for pharma research in London

    Boehringer Ingelheim launches AI centre for pharma research in London

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid